Company (location) |
Type of financing |
Number of shares, units or warrants (M) |
Amount raised (US$M) |
Investors; placement agents; details |
Date |
Total: $463.97M | |||||
Adial Pharmaceuticals Inc. (Charlottesville, Va.) |
Warrant exercise |
W for 0.233S |
$1.20 |
$1.2M from the voluntary exercise of previously outstanding warrants to purchase 243,100 shares of its common stock; additionally, 125,000 shares were issued as part of the cashless exercise of warrants |
1/25/19 |
Aimmune Therapeutics Inc. (Brisbane, Calif.) |
Equity investment |
N/A |
$40.00 |
Aimmune entered a $170 M loan agreement with an affiliate of KKR, a global investment firm; the loan will be advanced in three tranches with $40M funded at close, and $85M to follow upon FDA approval of AR-101 and satisfaction of other customary borrowing conditions; the remaining $45M will be at the company's option in 2020 upon the satisfaction of certain borrowing conditions |
1/7/19 |
Alpine Immune Sciences Inc. (Seattle) |
Private placement of common stock and warrants |
4.7S and W for 1.8S |
$25.30 |
$25.3M through the private placement of 4.7M shares and warrants to purchase 1.8M shares at a purchase price per unit of $5.37, led by Decheng Capital with participation from existing investors Orbimed Advisors, Frazier Healthcare Partners, Alpine Bioventures and BVF Partners LP; Piper Jaffray & Co. acted as sole placement agent |
1/17/19 |
Arch Biopartners Inc. (Toronto) |
Convertible note financing |
N/A |
$0.38 |
CA$500,000 (US$374,771) through a nonbrokered, unsecured convertible note financing |
1/25/19 |
Axsome Therapeutics Inc. (New York) |
At-the-market offering |
2.88S |
$23.30 |
$23.3M through the sale of 2.88M shares under its existing at-the-market (ATM) facility with Leerink Partners LLC |
1/9/19 |
Bio-Path Holdings Inc. (Houston) |
Registered direct offering and private placement |
0.648S and W for 0.324S |
$1.70 |
$1.7M registered direct offering of 648,302 shares of common stock at $2.65 per share; in a concurrent private placement, it is also issuing warrants to purchase up to 324,151 shares; H.C. Wainwright & Co. is exclusive placement agent; the company also closed a public offering of 8.6M shares priced at 13 cents each for proceeds of about $1.1M |
1/22/19 |
Can-Fite Biopharma Ltd. (Petach Tikva, Israel) |
Private placement |
2.2ADS |
$2.35 |
$2.35M through the placement of 2.2M American depositary shares at $1.05 apiece with a single institutional investor; H.C. Wainwright & Co. is acting as the exclusive placement agent |
1/22/19 |
Coherus Biosciences Inc. (Redwood City, Calif.; CHRS) |
Credit facility |
N/A |
$75.00 |
Entered $75M senior secured credit facility agreement with Healthcare Royalty Partners |
1/7/19 |
Correvio Pharma Corp. (Vancouver, British Columbia) |
At-the-market offering |
4.3S |
$11.65 |
$11.65M through an at-the-market offering of 4.3M shares at an average price of $2.71 each |
1/18/19 |
Esperite NV (Amsterdam) |
Private placement of convertible notes |
N/A |
$0.26 |
€0.23 (US$0.264) in a private placement of convertible notes, which included share subscription warrants attached; this is the 24th tranche of investments under a 2017 agreement with European Select Growth Opportunities Fund |
1/11/19 |
Immunogen Inc. (Waltham, Mass.) |
Royalty sale |
N/A |
$65.00 |
$65M through a sale of its residual rights to receive royalty payments on sales of Kadcyla (ado-trastuzumab emtansine, Roche Holding AG) to Ontario's municipal employees' pension plan Omers |
1/9/19 |
Immuron Ltd. (Melbourne, Australia) |
Australian government cash refund |
N/A |
$1.19 |
$1.19M cash refund from the Australian government for eligible research and development expenditure during its 2018 fiscal year |
1/9/19 |
Kiniksa Pharmaceuticals Ltd. (Hamilton, Bermuda) |
Private placement |
2S |
$36.60 |
$36.6M private placement of about 2M class A1 common shares to one or more existing shareholders affiliated with certain of Kiniksa's directors at a sale price equal to the price to the public in a concurrent public offering of class A common shares, which raised $48.39M |
1/30/19 |
Mesoblast Ltd. (Melbourne, Australia) |
Four-year credit facility |
N/A |
$15.00 |
$15M drawdown from its $75M credit facility with Hercules Capital Inc. |
1/15/19 |
Midatech Pharma plc (Abingdon, U.K.) |
Private placement |
103.9U |
$10.50 |
£8M (US$10.5M) through a subscription of new ordinary shares priced at 3.85 pence apiece; CMS Medical Venture Investment (HK) Ltd. and A&B (HK) Co. Ltd. have each conditionally subscribed for 103.9M units at the issue price, with each unit consisting of one new ordinary share and one warrant to subscribe for one new share |
1/30/19 |
Motif Bio plc (London) |
Warrant exercise |
0.7S |
$0.20 |
£152,626.80 (US$199,411.67) for the exercise of warrants representing 717,384 ordinary shares of 1 pence (US1.3 cents); the exercise price of warrants representing 642,384 ordinary shares was 20 pence per warrant, and the exercise price of warrants representing 75,000 ordinary shares was 32.2 pence each |
1/24/19 |
Nicox SA (Sophia Antipolis, France) |
Tranched bond financing |
N/A |
$22.80 |
€20M (US$22.8M) tranched bond financing with Kreos Capital, expected to extend its cash runway into 2021 |
1/28/19 |
Outlook Therapeutics Inc. (formerly Oncobiologics Inc.; Cranbury, N.J.) |
Private placement of common stock |
4.3S |
$4.00 |
Closed on the third tranche of four of its $20M private placement of common stock to Biolexis Pte Ltd., the company's largest investor, receiving $4M in cash in exchange for about 4.28M shares at 93 cents apiece; to date, the firm has received $16M |
1/3/19 |
Pharnext SA (Paris) |
Private placement |
1S |
$17.10 |
€15M (US$17.1M) financing from CB Lux via a private placement of about 1M new shares |
1/24/19 |
Prana Biotechnology Ltd. (Melbourne, Australia) |
Securities purchase agreement |
N/A |
$31.40 |
Securities purchase agreement for a lead investment by Life Biosciences LLC, of Boston, to raise up to approximately AU$44.5M (US$31.4M); it will initially invest $7.5M, with the agreement allowing the company to raise an additional $2M from other investors; a further AU$31M would be invested by Life Biosciences and other investors on exercise of short-term warrants being issued as part of the transaction |
1/3/19 |
Precision Therapeutics Inc. (Minneapolis) |
Loan and investment |
0.078S |
$1.00 |
$1M from CEO and director Carl Schwartz who provided a $950,000 loan under an amended and restated promissory note, which now covers advances of $1.3M, including a previous loan from November, and $50,000 through the purchase of 78,125 shares of the company's common stock at 64 cents per share |
1/22/19 |
Promis Neurosciences Inc. (Toronto) |
Private placement |
9.56U |
$1.64 |
CA$2.19M (US$1.64M) through a private placement of 9.56M units at CA23 cents each; each unit consists of one common share and one share purchase warrant entitling the holder to purchase one share at an exercise price of CA48 cents |
1/24/19 |
Recro Pharma Inc. (Malvern, Pa.) |
Debt funding |
N/A |
$40.00 |
Recro amended its existing credit facility with Athyrium Capital Management LP, which reinstates access to $40M in debt funding; the company had previously drawn down $60M |
1/3/19 |
Rezolute Inc. (Redwood City, Calif.) |
Preferred stock purchase agreement |
N/A |
$25.00 |
$25M preferred stock purchase agreement with Handok Inc. and Genexine Inc., two publicly traded South Korean-based pharmaceutical companies; each preferred share is priced at $5 and automatically converts into shares of the company's common stock at an implied per share price of 22 cents |
1/8/19 |
Theralase Technologies Inc. (Toronto) |
Private placement of units |
4.1U |
$1.40 |
$1.4M through a private placement of 4.1M units, consisting of a share and a warrant to buy an additional share, at 35 cents per unit |
1/9/19 |
Trevena Inc. (Chesterbrook, Pa.) |
Registered direct offering |
10S |
$10.00 |
$10M through an offering of 10M shares at $1 each to two health care-focused institutional investors |
1/31/19 |
Notes Currency conversions are based on exchange rates at the time of the deal. This chart includes only biotech companies that develop therapeutics. |